Propanc Biopharma (PPCB) 10-Q 14 Nov 24 2025 Q1 Quarterly report Financial data

Cover

Cover - $ / shares	3 Months Ended
	Sep. 30, 2024	Nov. 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	+61-03
Local Phone Number	9882-0780
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		789,899,183
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)
CURRENT ASSETS:
Cash	$ 9,268	$ 21,085
GST tax receivable	3,309	2,950
Prepaid expenses and other current assets	8,957	1,406
TOTAL CURRENT ASSETS	21,534	25,441
Deferred offering costs	27,117	27,117
Security deposit - related party	2,081	2,008
TOTAL ASSETS	63,644	72,365
CURRENT LIABILITIES:
Accounts payable	1,238,589	1,213,335
Accrued expenses and other payables	875,199	792,190
Accrued interest	111,652	94,612
Notes payable, net of discount	213,109	204,694
Convertible notes, net of discounts and including put premiums	381,789	399,325
Embedded conversion option liabilities	134,234	133,886
Employee benefit liability	677,902	639,371
TOTAL CURRENT LIABILITIES	4,101,244	3,792,782
NON-CURRENT LIABILITIES:
TOTAL NON-CURRENT LIABILITIES	70,485	58,642
TOTAL LIABILITIES	4,171,729	3,851,424
Commitments and Contingencies (See Note 8)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 688,022,017 and 478,802,488 shares issued and outstanding as of September 30, 2024 and June 30, 2024, respectively	688,022	478,802
Additional paid-in capital	61,132,262	61,217,255
Accumulated other comprehensive income	1,170,638	1,269,581
Accumulated deficit	(67,052,530)	(66,698,220)
Treasury stock ($0.001 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(4,108,085)	(3,779,059)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	63,644	72,365
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Related Party [Member]
CURRENT ASSETS:
Operating lease right-of-use assets, net - related party	12,912	17,799
CURRENT LIABILITIES:
Loan from former director - related party	227,328	71,629
Operating lease liability - related party, current portion	14,185	19,362
NON-CURRENT LIABILITIES:
Loan payable - long-term - related party, net of discount	70,485	58,642
Nonrelated Party [Member]
CURRENT LIABILITIES:
Loan from former director - related party	145,091	145,091
Former Director [Member]
CURRENT LIABILITIES:
Loan from former director - related party	51,326	49,528
Due to former director - related party	$ 30,840	$ 29,759

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Jun. 30, 2024
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	688,022,017	478,802,488
Common stock, shares outstanding	688,022,017	478,802,488
Treasury stock price per share	$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	220,759	393,828
Occupancy expenses - related party	8,317	7,149
Research and development	61,714	16,242
TOTAL OPERATING EXPENSES	290,790	417,219
LOSS FROM OPERATIONS	(290,790)	(417,219)
OTHER INCOME (EXPENSE)
Interest expense	(86,230)	(178,234)
Interest income	1	17
Derivative expense	(27,182)	(77,721)
Change in fair value of derivative liabilities	52,787	303,929
Gain (loss) on extinguishment of debt, net	(11,319)	34,310
Foreign currency transaction gain (loss)	8,423	(15,948)
TOTAL OTHER INCOME (EXPENSE), NET	(63,520)	66,353
LOSS BEFORE TAXES	(354,310)	(350,866)
Tax benefit
NET LOSS	(354,310)	(350,866)
Deemed Dividend		(142,575)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (354,310)	$ (493,441)
BASIC NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ 0	$ (0.04)
DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ 0	$ (0.04)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING	590,937,498	10,989,681
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	590,937,498	10,989,681
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	$ (98,943)	$ 73,674
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	(98,943)	73,674
TOTAL COMPREHENSIVE LOSS	$ (453,253)	$ (419,767)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance at Jun. 30, 2023			$ 6,031	$ 1,621	$ 60,311,502	$ (64,684,732)	$ 1,294,876	$ (46,477)	$ (3,117,179)
Balance, shares at Jun. 30, 2023		1	6,031,250	1,621,653
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 4,899	$ 626	223,665				229,190
Issuance of common stock for conversion of convertible debt and accrued interest, shares			4,898,307	626,229
Issuance of common stock for alternate cashless exercise of warrants			$ 2,282		(2,282)
Issuance of common stock for alternate cashless exercise of warrants, shares			2,282,000
Issuance of common stock for issuable shares			$ 1,621	$ (1,621)
Issuance of common stock for issuable shares, shares			1,621,653	(1,621,653)
Reclassification of put premium upon debt conversion					34,838				34,838
Relative fair value of warrant granted in connection with a loan payable - related party					141,084				141,084
Foreign currency translation gain (loss)							73,674		73,674
Deemed dividend upon alternate cashless exercise of warrants					142,575	(142,575)
Net loss						(350,866)			(350,866)
Balance at Sep. 30, 2023			$ 14,833	$ 626	60,851,382	(65,178,173)	1,368,550	(46,477)	(2,989,259)
Balance, shares at Sep. 30, 2023		1	14,833,210	626,229
Balance at Jun. 30, 2024			$ 478,802		61,217,255	(66,698,220)	1,269,581	(46,477)	(3,779,059)
Balance, shares at Jun. 30, 2024		1	478,802,488
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 194,220		(94,329)				99,891
Issuance of common stock for conversion of convertible debt and accrued interest, shares			194,219,529
Reclassification of put premium upon debt conversion					9,336				9,336
Foreign currency translation gain (loss)							(98,943)		(98,943)
Net loss						(354,310)			(354,310)
Issuance of common stock for services			$ 15,000						15,000
Issuance of common stock for services, shares			15,000,000
Balance at Sep. 30, 2024			$ 688,022		$ 61,132,262	$ (67,052,530)	$ 1,170,638	$ (46,477)	$ (4,108,085)
Balance, shares at Sep. 30, 2024		1	688,022,017

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (354,310)	$ (350,866)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance of common stock for services	7,500
Foreign currency transaction loss (gain)	(8,423)	15,948
Depreciation expense		134
Amortization of debt discounts	56,983	69,457
Amortization of right-of-use assets	5,534	5,128
Change in fair value of derivative liabilities	(52,787)	(303,929)
Derivative expense	27,182	77,721
Loss (gain) on extinguishment of debt, net	11,319	(34,310)
Non-cash interest expense	2,548	1,437
Accretion of put premium		88,846
Changes in Assets and Liabilities:
GST receivable	(251)	132
Prepaid expenses and other assets		(14,468)
Refundable advance deposit		(116,169)
Accounts payable	(18,797)	148,834
Employee benefit liability	15,317	12,275
Accrued expenses and other payables	54,457	55,693
Accrued interest	24,093	15,712
Operating lease liability	(5,880)	(5,032)
NET CASH USED IN OPERATING ACTIVITIES	(235,515)	(333,457)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	60,000	220,000
Repayment of convertible note		(142,909)
Proceeds from note payable		120,000
Proceeds from loans payable - related parties	155,699	153,256
NET CASH PROVIDED BY FINANCING ACTIVITIES	215,699	350,347
Effect of exchange rate changes on cash	7,999	(20,312)
NET DECREASE IN CASH	(11,817)	(3,422)
CASH AT BEGINNING OF PERIOD	21,085	10,047	$ 10,047
CASH AT END OF PERIOD	9,268	6,625	$ 21,085
Supplemental Disclosure of Cash Flow Information
Interest	2,606	2,713
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of put premium related to conversions of convertible notes	9,336	34,838
Conversion of convertible notes and accrued interest to common stock	51,978	114,131
Debt discounts related to derivative liability	60,000	70,000
Relative fair value of warrant granted in connection with a loan payable - related party		141,084
Deemed dividend upon alternate cashless exercise of warrants		142,575
Issuance of common stock for prepaid service	$ 7,500

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2024, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2024 and 2023 and cash flows for the three months ended September 30, 2024 and 2023 and our consolidated financial position at September 30, 2024 have been made. The Company’s results of operations for the three months ended September 30, 2024 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2025. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2024. The June 30, 2024 balance sheet is derived from those statements. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2024 and still remains inactive. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of September 30, 2024 and 2023, the Company recognized a cumulative exchange gain (loss) of approximately $ 677,000 669,000 As of September 30, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES September 30, 2024 June 30, 2024 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6936 0.6693 Average exchange rate for the period USD : AUD exchange rate 0.6668 0.6557 The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2024 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME Foreign Balance, June 30, 2024 $ 1,269,581 Unrealized foreign currency translation loss (98,943 ) Ending balance, September 30, 2024 $ 1,170,638 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no Refundable Advance Deposit In August 2023, the Company paid a refundable advance deposit of $ 120,958 120,958 Deferred Offering Costs The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of September 30, 2024 and June 30, 2024, the Company had recorded $ 27,117 Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of September 30, 2024 and June 30, 2024, the Company was owed $ 3,309 2,950 Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 61,714 16,242 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt. Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS September 30, 2024 September 30, 2023 (Unaudited) (Unaudited) Stock Options 0.06 0.06 Stock Warrants with no designations 15,003,306 15,003,306 Series A Warrants as if converted at alternate cashless exercise price 1,990,353,990 1,994,343,990 Series B Warrants 16 16 Series C Warrants as if converted at alternate cashless exercise price * 9,175,999,954 9,175,999,954 Unvested restricted stock 0.06 0.06 Convertible Debt 1,823,504,274 210,849,945 Total 13,004,861,540.12 11,396,197,211.12 * Only convertible ratably upon exercise of Series B Warrants Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements or disclosures. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited)

GOING CONCERN

GOING CONCERN	3 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the three months ended September 30, 2024, the Company had no revenues, had a net loss of $ 354,310 235,515 4,079,710 4,108,085 67,052,530 The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following As of September 30, 2024 and June 30, 2024. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, 2024 June 30, 2024 (Unaudited) Office equipment at cost $ 26,471 $ 25,543 Less: Accumulated depreciation (26,471 ) (25,543 ) Total property, plant, and equipment $ - $ - Depreciation expense for the three months ended September 30, 2024 and 2023 were $ 0 134

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	3 Months Ended
	Sep. 30, 2024
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at September 30, 2024 and June 30, 2024 were $ 30,840 29,759

LOANS

LOANS	3 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
LOANS	NOTE 5 – LOANS Loan from Former Director - Related Party Loan from the Company’s former director at September 30, 2024 and June 30, 2024 were $ 51,326 49,528 Loans payable - Related Parties Between November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 71,629 85,000 57,639 Effective August 1, 2024, the Company entered into and closed a loan agreement (the “Loan”) with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 150,000 98,060 November 1, 2024 12 18 35 The loans payable – related parties amounted to $ 227,328 71,629 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Loan payable -long-term- Related Party On July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 3 July 5, 2026 10 15,000,000 0.01 15,000,000 141,084 0.119 0.01 zero 3.00 4.59 268 143,000 Accrued interest from this loan amounted to $ 15,158 46,470 153,256 94,614 58,642 Accrued interest from this loan amounted to $ 19,020 11,843 153,256 82,771 70,485 Loan Payable Crown Bridge Securities Purchase Agreement Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $ 65,280 15 65,280 43,520 48,009 45,541 Loans Payable - others In June 2024, the Company entered into loan agreements with two investors who loaned the Company an aggregate of $ 120,000 79,811 June 2025 12 79,811 3,079 665 The aggregate principal outstanding on the above loans was $ 145,091 Loan in default The Crown Bridge Note is currently past due and in default, consisting of $ 65,280 48,009 15

NOTES PAYABLE AND CONVERTIBLE N

NOTES PAYABLE AND CONVERTIBLE NOTES	3 Months Ended
	Sep. 30, 2024
Notes Payable And Convertible Notes
NOTES PAYABLE AND CONVERTIBLE NOTES	NOTE 6 – NOTES PAYABLE AND CONVERTIBLE NOTES Promissory Note On August 15, 2023, the Company issued to an institutional investor (the “August 2023 Lender”) a 10 % original issue discount promissory note (the “Promissory Note”) in consideration for $ 120,000 , which has a principal face amount of $ 132,000 , matured on November 15, 2023 and accrued interest at a rate of 10 % per annum, and was increased to 18 % due to the event of a default. The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment. The Promissory Note contains certain customary events of default set forth in the Promissory Note, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Promissory Note. On May 7, 2024, the August 2023 Lender notified the Company that the 130 % default repayment plus interest will be waived and shall extend the maturity of the Promissory Note to September 30, 2024. As of the date of filing this report, such Promissory Note is past due and currently in default. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Accrued interest from this note amounted to $ 18,863 15,536 12,000 132,000 0 132,000 1800 Diagonal Lending Promissory Notes On May 24, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 On June 10, 2024, the Company entered into a 15 49,200 8,200 6,000 35,000 22 28,290 7,072.50 56,580 7,072.50 The Company has right to accelerate payments or prepay in full at any time with no prepayment penalty. At any time following an event of default, the noteholder shall have the right, to convert all or any part of the outstanding and unpaid amount of these notes into shares of common stock. The conversion price of the above notes shall mean 65 35 4.99 150 As of September 30, 2024 and June 30, 2024 the total balance of these 1800 Diagonal Lending promissory notes amounted to $ 98,400 4,913 1,193 The total balance of the above three promissory notes, net of unamortized discount of $ 17,291 213,109 25,706 204,694 Convertible Notes The Company’s convertible notes outstanding at September 30, 2024 and June 30, 2024 were as follows: SCHEDULE OF CONVERTIBLE NOTES September 30, 2024 (Unaudited) June 30, 2024 Convertible notes and debenture $ 334,625 $ 313,550 Unamortized discounts (68,129 ) (38,854 ) Premium, net 115,293 124,629 Convertible notes, net $ 381,789 $ 399,325 ONE44 Capital Securities Purchase Agreements August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 August 15, 2022 10 February 14, 2023 Securities Purchase Agreement On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 111,111 , such principal and the interest thereon were convertible into shares of the common stock at the option of ONE44 any time after the six-month anniversary of the February 14, 2023 ONE44 Note. The transaction contemplated by such purchase agreement closed on February 14, 2023. The February 14, 2023 One44 Note contained an original issue discount amount of $ 11,111 . Pursuant to the terms of such purchase agreement, the Company paid $ 5,500 for ONE44’s legal fees. The Company used the net proceeds from the February 14, 2023 ONE44 Note for general working capital purposes. The maturity date of the February 14, 2023 One44 Note was February 14, 2024. The February 14, 2023 ONE44 Note bore interest at a rate of 10 % per annum, which interest was payable in shares of common stock, but was not payable until the maturity date or upon acceleration or by prepayment of such note. The February 14, 2023 One44 Note was fully converted in fiscal year 2024. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) December 8, 2023 Securities Purchase Agreement On December 8, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “December 8, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 150,000 15,000 7,500 10 The following terms shall apply to all of the above ONE44 note: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120 135 The conversion price for the above ONE44 notes ranges from 60 65 35 40 4.99 133,305 100,000 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 financing agreements was $ 119,300 6,726 148,811 9,909 98,311 The total principal amount outstanding under the above ONE44 financing agreements was $ 105,800 8,645 13,500 841 9,000 GS Capital Partners Securities Purchase Agreements August 23, 2023 Securities Purchase Agreement On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 77,500 5,000 2,500 The maturity date of the GS Capital Note was February 23, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share, provided that the fixed price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) October 12, 2023 Securities Purchase Agreement On October 12, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 61,000 3,500 2,500 The maturity date of the GS Capital Note was April 12, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share, provided that the fixed price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. April 12, 2024 Securities Purchase Agreement On April 12, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 27,500 2,500 The maturity date of the GS Capital Note is October 12, 2024 . The GS Capital Note shall bear interest at a rate of 8 % per annum, which interest may be paid by the Company to GS Capital in shares of common stock but shall not be payable until the GS Capital Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment. The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share, provided that the fixed price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default. August 2, 2024 Securities Purchase Agreement On August 2, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 33,000 3,000 The maturity date of the GS Capital Note is February 2, 2025 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share, provided that the fixed price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. September 20, 2024 Securities Purchase Agreement On September 20, 2024, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 33,000 3,000 The maturity date of the GS Capital Note is March 20, 2025 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0003 per share, provided that the fixed price will be reduced to $0.0001 per share in the event that the market price of the Common Stock trades below $0.0003 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) The following terms shall apply to all of the above GS Capital notes: Pursuant to the above GS Capital notes, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99 Additionally, the conversion prices of the above GS Capital notes will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. The effective conversion price of the outstanding GS Capital notes are 60 40 The above GS Capital notes were bifurcated from the embedded conversion option which was recorded as derivative liabilities at fair value. During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above GS Capital notes were $ 110,500 8,364 130,800 8,700 1,254 3,832 110,500 The total principal outstanding and accrued interest under the above GS Capital notes were $ 145,700 7,902 30,800 2,212 66,000 One GS Capital note with principal amount of $ 52,200 24 104 LLC Securities Purchase Agreement March 5, 2024 Securities Purchase Agreement Effective March 5, 2024, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) with 104 LLC (“104”), pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $ 50,000 46,875 3,125 7,500 March 1, 2025 8 16 June 20, 2024 Securities Purchase Agreement Effective June 20, 2024, Company entered into and closed a securities purchase agreement with 104 LLC, pursuant to which 104 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $ 33,750 30,375 3,375 5,200 June 20, 2025 8 16 The principal and interest on the notes are convertible into shares of common stock of the Company at the option of 104 at any time following the issuance date of the notes (the “Conversion Shares”) at a price per share equal to 65 35 4.99 45,096 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) During the first 60 days following the date of the notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes. The 104 notes contain certain events of default, including failure to pay principal and interest when due, failure to timely issue the conversion shares, failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, failure to comply with its reporting requirements with the U.S. Securities and Exchange Commission, a breach of certain covenants in the purchase agreement, default by the Company under any other note issued to the Investor, as well as certain customary events of default set forth in the notes, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, and liquidation. Upon an event of default, the notes will become immediately due and payable by the Company. The total principal amount outstanding under the above 104 financing agreements was $ 83,750 1,429 83,125 0 625 4,000 Outstanding convertible notes in default Outstanding convertible notes for total principal amount of $ 83,000 maturity dates between February 23, 2024 and April 12, 2024 Amortization of debt discounts The Company recorded $ 66,000 92,500 0 88,846 Amortization of all debt discounts for the three months ended September 30, 2024 and 2023 was $ 56,983 69,457 The Company reclassified $ 9,336 34,838

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	3 Months Ended
	Sep. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its certificate of incorporation, as amended (the “Certificate of Incorporation”), which increased the Company’s authorized capital stock. Such certificate of amendment increased the number of authorized shares of common stock from 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its Certificate of Incorporation, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of common stock from 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Of the total preferred shares authorized, 500,000 On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No no Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $ 0.01 One No Common Stock: Shares issued for conversion of convertible debt From July 1, 2024 through September 30, 2024, the Company issued an aggregate of 194,219,529 0.0002 44,925 7,053 2,548 Included in the above conversion during the three months ended September 30, 2024, were principal aggregate amount of convertible notes of $ 30,800 2,212 798 79,176 45,365 34,046 11,319 The Company reclassified $ 9,336 The Company has 7,100,870,280 Shares issued for services On August 12, 2024, the Company entered into a consulting agreement with two consultants to provide investor relation services from August 12, 2024 to October 12, 2024 for a total fee of $ 7,500 15,000,000 0.001 15,000 7,500 7,500 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 0.078 0.039 0.117 0.117 4,250,000 497,240 248,620 0.06 248,620 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Stock Warrants: The following table summarizes warrant activity for the three months ended September 30, 2024: SUMMARY OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2024 15,003,396 $ 1.24 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2024 15,003,396 * $ 1.24 Exercisable at September 30, 2024 15,003,378 $ 1.24 Outstanding and Exercisable: Weighted average remaining contractual term 1.76 Aggregate intrinsic value $ - * The total warrants of 15,003,396 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 16 16 Series C warrants 64 46 Warrants with no class designation 15,003,306 15,003,306 Total 15,003,396 15,003,378 Stock Options: A summary of the Company’s option activity during the three months ended September 30, 2024 is presented below: SUMMARY OF STOCK OPTION ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2024 0.059 $ 4,533,000 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2024 0.059 $ 4,533,000 Exercisable at September 30, 2024 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 4.62 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 During the three months ended September 30, 2024 and 2023, the Company recognized stock-based compensation of $ 0 0 No PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Proposed Reverse Stock Split (Unaudited) On August 7, 2024, the Company received written consent in lieu of a meeting by the holders of a majority of the voting power of the Company’s outstanding capital stock as of August 7, 2024 and the Company’s Board of Directors approving such actions as are necessary for the Company to proceed to, and the Company accordingly intends to, effectuate and execute a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) (the “Reverse Stock Split”). The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio. SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT Historical per share data – (Pre- Split basis) Three months September 30, 2024 Three months Ended September 30, 2023 Net loss available to Common Stockholders $ 354,310 $ 493,441 Basic and diluted weighted average shares outstanding 590,937,498 10,989,681 Basic and diluted net loss per share $ 0.00 $ 0.04 The table below reflects the reverse split of 1:60,000. Historical per share data – (Post- Split basis) Three months September 30, 2024 Three months Ended September 30, 2023 Net loss available to Common Stockholders $ 354,310 $ 493,441 Basic and diluted weighted average shares outstanding 9,849 183 Basic and diluted net loss per share $ 35.97 $ 2,696.40

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2 5 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 45,775 2 On October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 On July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of the University. In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 1 53,200 53,806 - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion was 24 months. As of September 30, 2024 and June 30, 2024, the Company has $ 54,327 47,531 no Consulting Agreement On May 4, 2024, the Company entered into an Engagement Agreement (the “Agreement”) with EF Hutton LLC (the “Consultant”) which will act as an exclusive lead underwriter, financial advisor, placement agent and investment banker of the Company, whereby the Consultant will assist the Company to a public offering and uplisting of the Company’s equity, debt or equity derivative instruments (“Offering”). The engagement period shall end on the earlier of i) 12 months from the date of this agreement or ii) the final closing if any of the Offering. The Consultant will prepare an Underwriting Agreement (the “Underwriting Agreement”) covering the sale of up to $ 15 (a) Financing Fees: (i) For private equity and equity-linked placements, pay the Consultant a cash fee of eight percent ( 8.0 (ii) For debt placements, pay the Consultant a cash fee of six percent ( 6.0 (iii) As additional compensation for EF Hutton’s services, the Company shall issue to the Consultant or its designees at the closing warrants (the “Warrants”) to purchase that number of shares of Common Stock equal to three percent ( 3.0 five years PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Additionally, the Consultant shall be entitled to a cash fee equal to eight percent ( 8.0 (b) Merger, acquisition or sale of stock or assets (the “M&A Transaction”) Fees: The M&A Transaction fees shall be payable to the Consultant in cash at the closing or closings of the M&A Transaction to which it relates and shall be equal to five percent ( 5.0 The Company will be responsible for and will pay all expenses relating to the Offering as defined in the Agreement. Additionally, the Company will provide an expense advance (the “Advance”) to the Consultant of $ 50,000 25,000 25,000 25,000 Operating Leases On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 8 ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET September 30, 2024 (Unaudited) June 30, 2024 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (53,289 ) (48,402 ) Right-of-use asset, net $ 12,912 $ 17,799 Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY September 30, 2024 June 30, 2024 Office lease $ 66,201 $ 66,201 Reduction of lease liability (52,016 ) (46,839 ) Less: office lease, current portion (14,185 ) (19,362 ) Long term portion of lease liability $ - $ - Remaining future minimum lease payments under non-cancelable operating lease at September 30, 2024 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2025 $ 14,566 Imputed interest (381 ) Total operating lease liability $ 14,185 The weighted average remaining lease term for the operating lease is 0.51

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of September 30, 2024 and June 30, 2024, the Company owed its former director a total of $ 30,840 29,759 As of September 30, 2024 and June 30, 2024, the Company owed its former director a total of $ 51,326 49,528 Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a five-year 39,600 28,325 3,600 2,575 198,000 141,629 3,000 2,176 203,129 140,890 194,129 129,930 8,317 7,149 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Loans payable - Related Parties Between November 2023 and May 2024, an institutional investor affiliated with one of our directors, Josef Zelinger, loaned the Company an aggregate of $ 71,629 85,000 57,639 Effective August 1, 2024, the Company entered into and closed a loan agreement (the “Loan”) with an institutional investor affiliated with one of our directors, Josef Zelinger, pursuant to which the investor loaned the Company an aggregate principal amount of $ 150,000 98,060 November 1, 2024 12 18 35 Loan payable -long-term- Related Party July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 3 July 5, 2026 10 15,000,000 0.01 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz’s employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 309,313 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive, part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz was paid $ 4,481 3,205 17,714 3,344 3,557 2,372 On August 12, 2021, the Board approved a bonus of $ 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 73,387 48,905 107,937 71,929 25,000 16,070 150,000 102,195 217,540 145,599 Amended and Restated Employment Agreement On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with Mr. Nathanielsz for a term of three years 400,000 309,313 0.04 4,675,000 110 4,250,000 0.04 0.04 10 0.04 0.04 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Nathanielsz, effective as of July 1, 2022, (the “2022 Effective Date”). The Amended Agreement provides Mr. Nathanielsz with a base salary of $ 600,000 414,900 100 200 Amended and Restated Employment Agreement On May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years 54,000 41,580 0.02 4,250,000 100 0.02 0.02 10 0.02 0.02 As of September 30, 2024 and June 30, 2024, total accrued salaries of $ 161,500 112,016 148,000 97,044 Intercompany Loans All intercompany loans were made by the parent to the Company’s subsidiary, Propanc PTY LTD, none of which has been repaid as of September 30, 2024. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the consolidated balance sheet as accumulated other comprehensive income.

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	3 Months Ended
	Sep. 30, 2024
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 10 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through September 30, 2024. The Company primarily relied on funding from one convertible and two non-convertible debt lenders and received net proceeds after deductions of $ 6,000 60,000 57,639 98,060 28 27 45 The Company primarily relied on funding from four convertible and non-convertible debt lenders and received net proceeds after deductions of $ 34,500 150,000 70,000 120,000 153,256 30 14 24 32 Receivable Concentration As of September 30, 2024 and June 30, 2024, the Company’s receivables were 100 Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of fiscal year 2023. In 2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered the national phase in October 2018. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of September 30, 2024 and June 30, 2024, the Company’s operations are based in Camberwell, Australia; however, the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2024 and June 30, 2024, there has been no activity within this entity.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	3 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 145,700 110,500 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at September 30, 2024, the last trading day of the period ended September 30, 2024, was $ 0.0003 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the three September 30, 2024 Volatility 290 316 282 % Expected Remaining Term (in years) 0.50 0.01 0.47 Risk Free Interest Rate 4.43 4.88 4.65 5.53 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis As of September 30, 2024 and June 30, 2024: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 134,234 $ — $ — $ 134,234 Total $ 134,234 $ — $ — $ 134,234 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 133,886 $ — $ — $ 133,886 Total $ 133,886 $ — $ — $ 133,886 The following is a roll forward for the three months ended September 30, 2024 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2024 $ 133,886 Initial fair value of embedded conversion option derivative liability recorded as debt discount 60,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 27,182 Reduction of derivative liability upon debt conversion (34,047 ) Change in fair value included in statements of operations (52,787 ) Balance at September 30, 2024 $ 134,234

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS Shares issued for conversion of convertible debt In October 2024, the Company issued an aggregate of 101,877,166 0.0001 10,300 828 1,097

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2024, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 84 granted, allowed, or accepted patents and 6 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2024 and 2023 and cash flows for the three months ended September 30, 2024 and 2023 and our consolidated financial position at September 30, 2024 have been made. The Company’s results of operations for the three months ended September 30, 2024 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2025. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2024. The June 30, 2024 balance sheet is derived from those statements.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2024 and still remains inactive.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited)
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency translations are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per Accounting Standards Codification (“ASC”) 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). As of September 30, 2024 and 2023, the Company recognized a cumulative exchange gain (loss) of approximately $ 677,000 669,000 As of September 30, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES September 30, 2024 June 30, 2024 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6936 0.6693 Average exchange rate for the period USD : AUD exchange rate 0.6668 0.6557 The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2024 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME Foreign Balance, June 30, 2024 $ 1,269,581 Unrealized foreign currency translation loss (98,943 ) Ending balance, September 30, 2024 $ 1,170,638
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no
Refundable Advance Deposit	Refundable Advance Deposit In August 2023, the Company paid a refundable advance deposit of $ 120,958 120,958
Deferred Offering Costs	Deferred Offering Costs The Company complies with the requirements of ASC 340, Other Assets and Deferred Costs, with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized and consist principally of professional, underwriting and other expenses incurred through the balance sheet date that are directly related to the Company’s proposed public offering. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of September 30, 2024 and June 30, 2024, the Company had recorded $ 27,117
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2024 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit/Liability	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited)
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of September 30, 2024 and June 30, 2024, the Company was owed $ 3,309 2,950
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 61,714 16,242 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as a tax benefit, in operations, upon receipt.
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited)
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the convertible notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS September 30, 2024 September 30, 2023 (Unaudited) (Unaudited) Stock Options 0.06 0.06 Stock Warrants with no designations 15,003,306 15,003,306 Series A Warrants as if converted at alternate cashless exercise price 1,990,353,990 1,994,343,990 Series B Warrants 16 16 Series C Warrants as if converted at alternate cashless exercise price * 9,175,999,954 9,175,999,954 Unvested restricted stock 0.06 0.06 Convertible Debt 1,823,504,274 210,849,945 Total 13,004,861,540.12 11,396,197,211.12 * Only convertible ratably upon exercise of Series B Warrants
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements or disclosures.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF TRANSACTION EXCHANGE RATES	As of September 30, 2024 and June 30, 2024, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES September 30, 2024 June 30, 2024 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6936 0.6693 Average exchange rate for the period USD : AUD exchange rate 0.6668 0.6557
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME	The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2024 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME Foreign Balance, June 30, 2024 $ 1,269,581 Unrealized foreign currency translation loss (98,943 ) Ending balance, September 30, 2024 $ 1,170,638
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS September 30, 2024 September 30, 2023 (Unaudited) (Unaudited) Stock Options 0.06 0.06 Stock Warrants with no designations 15,003,306 15,003,306 Series A Warrants as if converted at alternate cashless exercise price 1,990,353,990 1,994,343,990 Series B Warrants 16 16 Series C Warrants as if converted at alternate cashless exercise price * 9,175,999,954 9,175,999,954 Unvested restricted stock 0.06 0.06 Convertible Debt 1,823,504,274 210,849,945 Total 13,004,861,540.12 11,396,197,211.12 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following As of September 30, 2024 and June 30, 2024. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, 2024 June 30, 2024 (Unaudited) Office equipment at cost $ 26,471 $ 25,543 Less: Accumulated depreciation (26,471 ) (25,543 ) Total property, plant, and equipment $ - $ -

NOTES PAYABLE AND CONVERTIBLE_2

NOTES PAYABLE AND CONVERTIBLE NOTES (Tables)	3 Months Ended
	Sep. 30, 2024
Notes Payable And Convertible Notes
SCHEDULE OF CONVERTIBLE NOTES	The Company’s convertible notes outstanding at September 30, 2024 and June 30, 2024 were as follows: SCHEDULE OF CONVERTIBLE NOTES September 30, 2024 (Unaudited) June 30, 2024 Convertible notes and debenture $ 334,625 $ 313,550 Unamortized discounts (68,129 ) (38,854 ) Premium, net 115,293 124,629 Convertible notes, net $ 381,789 $ 399,325

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	3 Months Ended
	Sep. 30, 2024
Equity [Abstract]
SUMMARY OF WARRANT ACTIVITY	The following table summarizes warrant activity for the three months ended September 30, 2024: SUMMARY OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2024 15,003,396 $ 1.24 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2024 15,003,396 * $ 1.24 Exercisable at September 30, 2024 15,003,378 $ 1.24 Outstanding and Exercisable: Weighted average remaining contractual term 1.76 Aggregate intrinsic value $ - * The total warrants of 15,003,396
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 16 16 Series C warrants 64 46 Warrants with no class designation 15,003,306 15,003,306 Total 15,003,396 15,003,378
SUMMARY OF STOCK OPTION ACTIVITY	A summary of the Company’s option activity during the three months ended September 30, 2024 is presented below: SUMMARY OF STOCK OPTION ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2024 0.059 $ 4,533,000 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2024 0.059 $ 4,533,000 Exercisable at September 30, 2024 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 4.62 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -
SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT	The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio. SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT Historical per share data – (Pre- Split basis) Three months September 30, 2024 Three months Ended September 30, 2023 Net loss available to Common Stockholders $ 354,310 $ 493,441 Basic and diluted weighted average shares outstanding 590,937,498 10,989,681 Basic and diluted net loss per share $ 0.00 $ 0.04 The table below reflects the reverse split of 1:60,000. Historical per share data – (Post- Split basis) Three months September 30, 2024 Three months Ended September 30, 2023 Net loss available to Common Stockholders $ 354,310 $ 493,441 Basic and diluted weighted average shares outstanding 9,849 183 Basic and diluted net loss per share $ 35.97 $ 2,696.40

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT OF USE ASSET	ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET September 30, 2024 (Unaudited) June 30, 2024 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (53,289 ) (48,402 ) Right-of-use asset, net $ 12,912 $ 17,799
SCHEDULE OF OPERATING LEASE LIABILITY	Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY September 30, 2024 June 30, 2024 Office lease $ 66,201 $ 66,201 Reduction of lease liability (52,016 ) (46,839 ) Less: office lease, current portion (14,185 ) (19,362 ) Long term portion of lease liability $ - $ -
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under non-cancelable operating lease at September 30, 2024 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2025 $ 14,566 Imputed interest (381 ) Total operating lease liability $ 14,185

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during the three September 30, 2024 Volatility 290 316 282 % Expected Remaining Term (in years) 0.50 0.01 0.47 Risk Free Interest Rate 4.43 4.88 4.65 5.53 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 134,234 $ — $ — $ 134,234 Total $ 134,234 $ — $ — $ 134,234 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 133,886 $ — $ — $ 133,886 Total $ 133,886 $ — $ — $ 133,886
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the three months ended September 30, 2024 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2024 $ 133,886 Initial fair value of embedded conversion option derivative liability recorded as debt discount 60,000 Initial fair value of embedded conversion option derivative liability recorded as derivative expense 27,182 Reduction of derivative liability upon debt conversion (34,047 ) Change in fair value included in statements of operations (52,787 ) Balance at September 30, 2024 $ 134,234

SCHEDULE OF TRANSACTION EXCHANG

SCHEDULE OF TRANSACTION EXCHANGE RATES (Details)	Sep. 30, 2024	Jun. 30, 2024
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6936	0.6693
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6668	0.6557

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)	3 Months Ended
	Sep. 30, 2024 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 1,269,581
Unrealized foreign currency translation loss	(98,943)
Ending balance	$ 1,170,638

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVES (Details)	Sep. 30, 2024
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS (Details) - shares		3 Months Ended
		Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		13,004,861,540.12	11,396,197,211.12
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		15,003,306	15,003,306
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,990,353,990	1,994,343,990
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		16	16
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	9,175,999,954	9,175,999,954
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,823,504,274	210,849,945
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)		3 Months Ended
	May 01, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Aug. 31, 2023
Accounting Policies [Abstract]
Reverse stock split	one-for-one thousand (1:1,000)
Foreign currency transaction, gain		$ 677,000	$ 669,000
Cash and cash equivalents		0		$ 0
Refundable advance deposit					$ 120,958
Allowance for recoverability of refundable advance deposit		120,958
Deferred offering cost		27,117		27,117
GST tax receivable		$ 3,309		$ 2,950
Common stock, par value		$ 0.001		$ 0.001
Research and development costs		$ 61,714	$ 16,242
Beneficial ownership conversion description		Each holder of the convertible notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
Beneficial ownership percentage		4.99%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 354,310	$ 350,866
Net cash used in operations	235,515	333,457
Working capital deficit	4,079,710
Stockholders' deficit	4,108,085	$ 2,989,259	$ 3,779,059	$ 3,117,179
Accumulated deficit	$ 67,052,530		$ 66,698,220

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 26,471	$ 25,543
Less: Accumulated depreciation	(26,471)	(25,543)
Total property, plant, and equipment

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense		$ 134

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Former Director [Member]
Defined Benefit Plan Disclosure [Line Items]
Due to related parties current	$ 30,840	$ 29,759

LOANS (Details Narrative)

LOANS (Details Narrative)			1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 01, 2024 USD ($)	Jul. 05, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	Aug. 01, 2024 AUD ($)	Jun. 30, 2024 AUD ($)	May 31, 2024 USD ($)	Nov. 30, 2023 USD ($)	Jul. 05, 2023 AUD ($)	Oct. 03, 2019
Debt instrument face amount				$ 30,800			$ 57,639	$ 85,000			$ 71,629	$ 71,629
Debt instrument interest rate stated percentage		10%											10%
Debt instrument strike price				4.99%
Settlement of convertible debt					$ 142,909
Interest payable current and non current				2,212
Amortization of debt discounts				56,983	69,457
Debt remaining			$ 313,550	334,625		$ 313,550
Remaining debt discount			38,854	68,129		38,854
Gain on extinguishment of debt				(11,319)	34,310
Crown Bridge Partners, LLC [Member]
Debt instrument face amount				$ 65,280
Debt instrument interest rate stated percentage				15%
Interest payable current and non current				$ 48,009
Loan Agreement [Member]
Loans payable			145,091	145,091		145,091
Debt instrument face amount			$ 79,811			$ 79,811			$ 150,000	$ 120,000
Debt instrument maturity date	Nov. 01, 2024
Debt instrument loan bears interest rate	12%
Debt instrument interest rate stated percentage	18%		12%			12%			18%	12%
Debt instrument strike price	35%
Interest payable current and non current			$ 665	3,079		$ 665
Debt remaining			$ 79,811	79,811		79,811
Debt instrument maturity date			June 2025
Letter Agreement [Member]
Debt instrument face amount	$ 98,060	$ 153,256											$ 230,000
Debt instrument maturity date		Jul. 05, 2026
Debt instrument interest rate stated percentage		10%											10%
Maturity term		3 years
Issue of warrants | shares		15,000,000
Share price | $ / shares		$ 0.01
Fair value adjustment of warrants		$ 141,084
Letter Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Settlement of convertible debt				143,000
Letter Agreement [Member] | Warrant [Member]
Stock valuation price per share | $ / shares		$ 0.119
Warrant exercise price | $ / shares		$ 0.01
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input		0											0
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]
Maturity term		3 years
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input		4.59											4.59
Letter Agreement [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]
Measurement input		268											268
Securities Purchase Agreement [Member]
Amortization of debt discounts				66,000	$ 92,500
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Debt instrument face amount			$ 65,280	65,280		65,280
Debt instrument interest rate stated percentage														15%
Interest payable current and non current			45,541	48,009		45,541
Convertible debt			65,280			65,280
Gain on extinguishment of debt				43,520
Related Party [Member]
Loans payable			49,528	51,326		49,528
Loan payable			71,629	227,328		71,629	$ 57,639	$ 85,000			$ 71,629	$ 71,629
Interest payable current and non current			15,158	19,020		15,158
Amortization of debt discounts				11,843		46,470
Debt remaining			153,256	153,256		153,256
Remaining debt discount			94,614	82,771		94,614
Loan payable - long-term - related party, net of discount			$ 58,642	$ 70,485		$ 58,642

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Notes Payable And Convertible Notes
Convertible notes and debenture	$ 334,625	$ 313,550
Unamortized discounts	(68,129)	(38,854)
Premium, net	115,293	124,629
Convertible notes, net	$ 381,789	$ 399,325

NOTES PAYABLE AND CONVERTIBLE_3

NOTES PAYABLE AND CONVERTIBLE NOTES (Details Narrative)																		1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 15, 2025 USD ($)	Dec. 30, 2024 USD ($)	Dec. 15, 2024 USD ($)	Nov. 30, 2024 USD ($)	Sep. 20, 2024 USD ($)	Aug. 02, 2024 USD ($)	Jun. 20, 2024 USD ($)	Jun. 10, 2024 USD ($)	May 24, 2024 USD ($)	Apr. 12, 2024 USD ($)	Mar. 05, 2024 USD ($)	Dec. 08, 2023 USD ($)	Oct. 12, 2023 USD ($)	Aug. 23, 2023 USD ($)	Aug. 15, 2023 USD ($)	Feb. 14, 2023 USD ($)	Aug. 15, 2022 USD ($)	Aug. 31, 2023	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	May 31, 2024 USD ($)	May 04, 2024	Nov. 30, 2023 USD ($)	Jul. 05, 2023	Jun. 30, 2023 USD ($)
Principal amount																			$ 30,800			$ 57,639	$ 85,000	$ 71,629		$ 71,629
Debt instrument interest rate percentage																											10%
Accrued interest																			2,212
Amortization of debt discount																			56,983	$ 69,457
Debt remaining																			334,625		$ 313,550
Original issue discount																			68,129		38,854
Note payable, net of discount																			$ 213,109		204,694
Debt instrument debt default interest rate					24%														24%
Debt premium																			$ 115,293		124,629
Penalty amount																			30,000
Fee amount																			798
Derivative liabilities																			134,234		133,886
Conversion of stock amount converted																			9,336	34,838
Maximum [Member]
Debt instrument interest rate percentage																									8%
Securities Purchase Agreement [Member]
Amortization of debt discount																			66,000	92,500
Debt premium																			0	88,846
Convertible Notes One [Member]
Amortization of debt discount																			$ 56,983	$ 69,457
1800 Diagonal Lending LLC [Member]
Debt instrument original issue discount rate								15%	15%										150%
Original issue discounts amount								$ 8,200	$ 8,200
Principal amount								$ 49,200	$ 49,200
Debt instrument interest rate percentage								22%	22%
Accrued interest																			$ 4,913		1,193
Debt remaining																			$ 98,400		98,400
Legal and financing costs								$ 6,000	$ 6,000
Net proceeds								$ 35,000	$ 35,000
Debt instrument conversion rate																			65%
Debt instrument discount rate																			35%
Ownership limitations																			4.99%
1800 Diagonal Lending LLC [Member] | Forecast [Member]
Debt periodic payment				$ 28,290
Principal amount	$ 7,072.50	$ 7,072.50		7,072.50
Payment of debt				$ 56,580
ONE44 Capital LLC [Member]
Accrued interest																			$ 841		9,909
Debt premium																					100,000							$ 133,305
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member]
Principal amount												$ 150,000				$ 111,111	$ 110,000		105,800		119,300
Debt instrument maturity date																	Aug. 15, 2022
Debt instrument interest rate percentage												10%				10%	10%
Accrued interest																			8,645		6,726
Original issue discount												$ 15,000				$ 11,111	$ 10,000
Ownership limitations												4.99%
Legal fees												$ 7,500				$ 5,500	$ 5,500
Debt premium																			9,000		98,311
Default interest rate												24%
Debt instrument increase principal percentage												20%
Debt conversion converted instrument																			13,500		148,811
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument conversion rate												60%
Debt instrument discount rate												35%
Debt instrument debt default interest rate												120%
Penalty amount												$ 250
ONE44 Capital LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument conversion rate												65%
Debt instrument discount rate												40%
Debt instrument debt default interest rate												135%
Penalty amount												$ 500
GS Capital Partners, LLC [Member]
Accrued interest																			2,212		8,700
Derivative fixed interest rate																					1,254
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member]
Principal amount					$ 33,000	$ 33,000				$ 27,500			$ 61,000	$ 77,500
Debt instrument maturity date					Mar. 20, 2025	Feb. 02, 2025				Oct. 12, 2024			Apr. 12, 2024	Feb. 23, 2024
Debt instrument interest rate percentage					8%	8%				8%			8%	8%
Accrued interest																			7,902		8,364
Debt remaining																			$ 145,700		110,500
Original issue discount					$ 3,000	$ 3,000				$ 2,500			$ 3,500	$ 5,000
Debt instrument conversion rate					60%
Debt instrument discount rate					40%
Ownership limitations																			4.99%
Legal fees													$ 2,500	$ 2,500
Debt instrument increase principal percentage					20%
Conversion price, description					The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0003 per share, provided that the fixed price will be reduced to $0.0001 per share in the event that the market price of the Common Stock trades below $0.0003 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share, provided that the fixed price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.				The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.0017 per share, provided that the fixed price will be reduced to $0.001 per share in the event that the market price of the Common Stock trades below $0.0014 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. As of the date of filing this report, such GS Capital Note is past due and currently in default.			The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.015 per share, provided that the fixed price will be reduced to $0.01 per share in the event that the market price of the Common Stock trades below $0.0075 per share for ten consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share, provided that the fixed price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the note and unless the fixed price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default.
Fee amount																					3,832
Derivative liabilities																			$ 66,000		110,500
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument debt default interest rate					110%
Penalty amount					$ 250
GS Capital Partners, LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument debt default interest rate					125%
Penalty amount					$ 500
GS Capital Partners, LLC [Member] | August 10, 2017 Consulting Agreement [Member]
Debt conversion converted instrument																			30,800		130,800
Coventry Enterprises LLC Securities Purchase Agreement [Member] | Securities Purchase Agreement [Member]
Amount repaid for covertible debt																			52,200
104 LLC [Member] | Securities Purchase Agreement [Member]
Principal amount							$ 33,750				$ 50,000
Debt instrument maturity date							Jun. 20, 2025				Mar. 01, 2025
Debt Instrument description							the Company has the right to prepay the principal and accrued but unpaid interest due under the notes, at a one hundred ten percent (110%) premium of the face amount plus accrued and unpaid interest, which increases to (i) one hundred fifteen percent (115%) if prepaid after 60 days, but less than 91 days from the issuance date, (ii) one hundred twenty percent (120%) if prepaid after 90 days, but less than 121 days from the issuance date, (iii) one hundred twenty five percent (125%) if prepaid after 120 days, but less than 181 days from the issuance date. After this initial 180-day period, the Company does not have a right to prepay the notes.
Accrued interest																			0		1,429
Debt remaining																			83,125		83,750
Original issue discount							$ 3,375				$ 3,125
Legal and financing costs							$ 5,200				7,500
Principal amount																			4,000
Debt instrument conversion rate							65%
Debt instrument discount rate							35%
Ownership limitations							4.99%
Debt premium																					45,096
Purchase amount							$ 30,375				$ 46,875
Principal amount																			625
104 LLC [Member] | Securities Purchase Agreement [Member] | Minimum [Member]
Debt instrument interest rate percentage							8%				8%
104 LLC [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Debt instrument interest rate percentage							16%				16%
Loans Payable [Member]
Debt instrument original issue discount rate															10%
Original issue discounts amount															$ 120,000
Principal amount															$ 132,000
Debt instrument maturity date															Nov. 15, 2023
Debt instrument interest rate percentage															10%
Debt Instrument, Interest Rate, Increase (Decrease)															18%
Debt Instrument description															The Company had the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023 (including on the maturity date), unless the Company and the Lender agree to otherwise effect repayment.
Debt Instrument, Interest Rate During Period																		130%
Accrued interest																			18,863		15,536
Amortization of debt discount																					12,000
Debt remaining																			132,000
Original issue discount																			0		0
Note payable, net of discount																			132,000
Loans Payable [Member] | Promissory Note [Member]
Debt remaining																			213,109		204,694
Original issue discount																			17,291		$ 25,706
Loans Payable [Member] | 1800 Diagonal Lending LLC [Member]
Debt periodic payment			$ 28,290
Principal amount			7,072.50
Payment of debt			$ 56,580
Convertible Notes Payable [Member]
Convertible note																			$ 83,000
Maturity date description																			maturity dates between February 23, 2024 and April 12, 2024

SUMMARY OF WARRANT ACTIVITY (De

SUMMARY OF WARRANT ACTIVITY (Details)	3 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Balance | shares	15,003,396
Weighted Average Price Per Share, Outstanding, Balance | $ / shares	$ 1.24
Number of Shares, Issued | shares
Weighted Average Price Per Share, Issued | $ / shares
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised | $ / shares
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited | $ / shares
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Balance | shares	15,003,396	[1]
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 1.24
Number of Shares, Exercisable, Balance | shares	15,003,378
Weighted Average Price Per Share, Exercisable, Balance | $ / shares	$ 1.24
Weighted average remaining contractual term	1 year 9 months 3 days
Aggregate intrinsic value | $
[1]The total warrants of 15,003,396

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical) - shares	Sep. 30, 2024		Jun. 30, 2024
Equity [Abstract]
Number of Shares, Outstanding, Balance	15,003,396	[1]	15,003,396
[1]The total warrants of 15,003,396

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Sep. 30, 2024		Jun. 30, 2024
Class of Stock [Line Items]
Number of Warrants, Total	15,003,396	[1]	15,003,396
Exercisable, Total	15,003,378
Series A Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	10
Exercisable, Total	10
Series B Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	16
Exercisable, Total	16
Series C Warrants [Member]
Class of Stock [Line Items]
Number of Warrants, Total	64
Exercisable, Total	46
Common Stock Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of Warrants, Total	15,003,306
Exercisable, Total	15,003,306
[1]The total warrants of 15,003,396

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details)	3 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Balance | shares	0.059
Weighted Average Price Per Share, Outstanding, Balance	$ 4,533,000
Number of Shares, Granted | shares
Weighted Average Price Per Share, Granted
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired
Number of Shares, Outstanding, Balance | shares	0.059
Weighted Average Price Per Share, Outstanding, Ending balance	$ 4,533,000
Number of Shares, Exercisable, Balance | shares	0.059
Weighted Average Price Per Share, Exercisable, Balance	$ 4,533,000
Weighted average remaining contractual term	4 years 7 months 13 days
Weighted average fair value of options granted during the period
Aggregate intrinsic value | $

SCHEDULE OF LOSS PER SHARE BASI

SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net loss available to Common Stockholders	$ (354,310)	$ (493,441)
Basic weighted average shares outstanding	590,937,498	10,989,681
Diluted weighted average shares outstanding	590,937,498	10,989,681
Basic net loss per share	$ 0	$ (0.04)
Diluted net loss per share	$ 0	$ (0.04)
Pre-Reverse Stock Split [Member]
Net loss available to Common Stockholders	$ 354,310	$ 493,441
Basic weighted average shares outstanding	590,937,498	10,989,681
Diluted weighted average shares outstanding	590,937,498	10,989,681
Basic net loss per share	$ 0	$ 0.04
Diluted net loss per share	$ 0	$ 0.04
Post-Reverse Stock Split [Member]
Net loss available to Common Stockholders	$ 354,310	$ 493,441
Basic weighted average shares outstanding	9,849	183
Diluted weighted average shares outstanding	9,849	183
Basic net loss per share	$ 35.97	$ 2,696.40
Diluted net loss per share	$ 35.97	$ 2,696.40

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)				1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 12, 2024 USD ($) $ / shares shares	Aug. 07, 2024	May 01, 2023	May 31, 2019 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	May 31, 2024 USD ($)	Nov. 30, 2023 USD ($)	Mar. 31, 2023 shares	Sep. 21, 2022 shares	Sep. 20, 2022 shares	May 18, 2022 shares	May 17, 2022 shares
Class of Stock [Line Items]
Common stock shares authorized					10,000,000,000		10,000,000,000						10,000,000,000	3,000,000,000	3,000,000,000	1,000,000,000
Number of preferred stock authorized shares													1,500,005		1,500,005
Preferred stock, shares authorized					1,500,005		1,500,005								3,001,500,005
Total number of authorized shares													10,001,500,005
Reverse stock split		reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) (the “Reverse Stock Split”).	one-for-one thousand (1:1,000)
Preferred stock, par value | $ / shares					$ 0.01		$ 0.01
Principal amount					$ 30,800			$ 57,639	$ 85,000	$ 71,629	$ 71,629
Accrued interest | $					2,212
Conversion fees | $					798
Loss on extinguishment debt conversion | $					45,365
Debt conversion fair value | $					34,046
Gain (loss) on extinguishment of debt | $					11,319	$ (34,310)
Reclassified from premium liabilities to additional paid in capital | $					$ 9,336
Common stock, par value | $ / shares					$ 0.001		$ 0.001
Restricted stock units, value | $ / shares
Company recognized stock-based compensation | $					$ 0	0
Unvested stock option expense | $					$ 0	$ 0
Stock options granted					0
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance					234
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, shares				0.117
Restricted stock units, value | $ / shares				$ 4,250,000
Fair value granted, shares | $				$ 497,240
Unrecognized restricted stock units expense | $					$ 248,620		$ 248,620
Restricted stock units not yet vested, shares | $					$ 248,620
Unvested Restricted Stock Units [Member]
Class of Stock [Line Items]
Unvested restricted stock units					0.06
Chief Executive Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares				0.078
Chief Scientific Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares				0.039
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance					7,100,870,280
Consulting Agreement [Member]
Class of Stock [Line Items]
Number of shares issued	15,000,000
Monthly Fee | $	$ 7,500
Common stock, par value | $ / shares	$ 0.001
Stock Issued During Period, Value, New Issues | $	$ 15,000
Stock-based compensation | $					$ 7,500
Prepaid stock-based compensation | $					$ 7,500
Convertible Debt [Member]
Class of Stock [Line Items]
Number of shares issued					194,219,529
Average contractual conversion prices | $ / shares					$ 0.0002
Principal amount | $					$ 44,925
Accrued interest | $					7,053
Conversion fees | $					2,548
Debt instrument fair value | $					$ 79,176
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					500,000
Preferred stock shares outstanding					0		0					0
Preferred stock shares issued					0		0
Shares issued					0		0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					5		5
Preferred stock, par value | $ / shares					$ 0.01		$ 0.01
Preferred stock shares outstanding					1		1
Preferred stock shares issued					1		1
Shares issued					0		0

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET (Details) - Related Party [Member] - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(53,289)	(48,402)
Right-of-use asset, net	$ 12,912	$ 17,799

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - Related Party [Member] - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(52,016)	(46,839)
Less: office lease, current portion	(14,185)	(19,362)
Long term portion of lease liability

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Sep. 30, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2025	$ 14,566
Imputed interest	(381)
Total operating lease liability	$ 14,185

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

3 Months Ended

12 Months Ended

May 04, 2024 USD ($)

Jul. 27, 2022 USD ($)

Jul. 27, 2022 EUR (€)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Oct. 01, 2020 USD ($)

Oct. 01, 2020 EUR (€)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

Jul. 31, 2023 USD ($)

Jul. 31, 2023 EUR (€)

Mar. 31, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Aug. 31, 2022 USD ($)

Aug. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

Jun. 30, 2012

Sep. 30, 2024 USD ($)

Sep. 30, 2023 USD ($)

Jun. 30, 2024 USD ($)

Jul. 05, 2023

Total litigation penalty amount

$ 30,000

Royalties percentage

2%

2%

Unreimbursed lab fees

54,327

$ 47,531

Royalty fees

0

0

Cash fee percentage

10%

Warrants term

5 years

Deferred offering cost

27,117

$ 27,117

Payments for rent

$ 8,317

$ 7,149

Incremental borrowing rate

8%

8%

Weighted average remaining lease term

6 months 3 days

Accounting Standards Update 2016-02 [Member]

Operating lease right of use asset

$ 66,201

Operating lease liabilities

$ 66,201

Consultant [Member]

Sale of stock percent

5%

Expenses advance

$ 50,000

Deferred offering cost

$ 25,000

Maximum [Member]

Cash fee percentage

8%

Common Stock [Member]

Sale of stock percent

3%

Equity and Equity Linked Placements [Member]

Cash fee percentage

8%

Debt Placements [Member]

Cash fee percentage

6%

University of Jaen [Member]

Payment for services

$ 30,268

€ 25,837

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5%

1-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

Royalty percentage

2%

2%

Research Agreement [Member] | University of Jaen [Member]

Payment for services

$ 53,806

€ 53,200

Royalty percentage

1%

1%

Underwriting Agreement [Member] | EF Hutton LLC [Member]

Sale of underwriting agreements

$ 15,000,000

Merger Acquisition Agreement [Member] | Consultant [Member]

Expenses advance

25,000

Initial Payable [Member] | Consultant [Member]

Expenses advance

$ 25,000

New Three-Year Operating Lease Agreement [Member]

Lessee operating lease term

3 years

Payments for rent

$ 2,176

$ 3,000

From 2012 through the 2014 [Member]

Total litigation penalty amount

$ 10,000

Installment 1 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services | €

€ 5,000

Installment 1 [Member] | Research Agreement [Member]

Payment for services

$ 18,407

€ 18,200

Installment 2 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 5,858

€ 5,000

Installment 2 [Member] | Research Agreement [Member]

Payment for services

$ 8,091

€ 8,000

Installment 3 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 3 [Member] | Research Agreement [Member]

Payment for services

$ 7,080

€ 7,000

Installment 4 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 4 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

Installment 5 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)																						1 Months Ended			3 Months Ended			12 Months Ended
	Aug. 01, 2024 USD ($)	Jul. 05, 2023 USD ($) $ / shares shares	Oct. 26, 2022 USD ($)	Oct. 26, 2022 AUD ($)	Aug. 01, 2022 USD ($)	Aug. 01, 2022 AUD ($)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Aug. 12, 2021 USD ($) shares	May 14, 2019 USD ($) $ / shares shares	May 14, 2019 AUD ($) shares	Mar. 16, 2018 USD ($)	Mar. 16, 2018 AUD ($)	Feb. 01, 2018 USD ($)	Feb. 01, 2018 AUD ($)	May 05, 2016 USD ($)	May 05, 2016 AUD ($)	Feb. 25, 2016 USD ($)	Feb. 25, 2016 AUD ($)	Feb. 25, 2015 USD ($)	Feb. 25, 2015 AUD ($)	Jan. 31, 2024 USD ($)	Jan. 31, 2024 AUD ($)	May 31, 2019 shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2024 AUD ($) shares	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) shares	Jun. 30, 2024 AUD ($) shares	Jun. 30, 2023 USD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Sep. 30, 2024 AUD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	Aug. 01, 2024 AUD ($)	Jun. 30, 2024 AUD ($)	May 31, 2024 USD ($)	May 04, 2024	Nov. 30, 2023 USD ($)	Jul. 05, 2023 AUD ($)	May 05, 2016 AUD ($)
Related Party Transaction [Line Items]
Payments for rent | $																									$ 8,317		$ 7,149
Investor loan, value																									$ 30,800										$ 57,639	$ 85,000			$ 71,629		$ 71,629
Debt instrument interest rate stated percentage		10%																																								10%
Debt instrument strike price																									4.99%	4.99%
Bonus payable																						$ 102,195	$ 150,000					$ 16,070	$ 25,000	$ 48,905	$ 73,387
Exercise price | $ / shares
Granted exercise price | $ / shares
Accrued salaries																									$ 112,016			97,044						$ 161,500				$ 148,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments form related party | $																																	$ 221,890
Bonus payable																																$ 166,418	$ 422,610
Remaining bonus amount																												145,599	$ 217,540	$ 71,929	$ 107,937
Restricted stock shares of common stock																								0.078
Maximum [Member]
Related Party Transaction [Line Items]
Debt instrument interest rate stated percentage																																								8%
Loan Agreement [Member]
Related Party Transaction [Line Items]
Investor loan, value																												$ 79,811									$ 150,000	$ 120,000
Debt instrument maturity date	Nov. 01, 2024
Debt instrument loan bears interest rate	12%
Debt instrument interest rate stated percentage	18%																											12%									18%	12%
Debt instrument strike price	35%
Letter Agreement [Member]
Related Party Transaction [Line Items]
Investor loan, value	$ 98,060	$ 153,256																																								$ 230,000
Debt instrument maturity date		Jul. 05, 2026
Debt instrument interest rate stated percentage		10%																																								10%
Term of agreement		3 years
Issue of warrants		15,000,000
Share price | $ / shares		$ 0.01
Nathanielsz Employment Agreement [Member]
Related Party Transaction [Line Items]
Expired date																				Feb. 25, 2019	Feb. 25, 2019
Base salary per month | $																					$ 25,000
Annual salary			$ 414,900	$ 600,000																$ 205,680	$ 300,000
Percentage of pension of monthly salary																														9.50%	9.50%
Percentage of bonus of annual base salary																									200%	200%
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Annual salary					$ 414,900	$ 600,000						$ 274,240	$ 400,000
Percentage of bonus of annual base salary																				200%	200%				100%	100%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Annual salary					309,313	400,000						$ 205,680	$ 300,000
Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable | $																																$ 316,957
Services Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																									0.02	0.02		0.02	0.02
Services Agreement [Member] | Initial Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock										0.02	0.02
Services Agreement [Member] | Additional Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock										0.02	0.02
Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																									0.04	0.04
Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock										0.04	0.04																	0.04	0.04
Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock unit issuable										0.04	0.04
North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract																5 years																											5 years
Operating leases rent expense, minimum rentals																$ 28,325	$ 39,600
Goods and service tax																2,575	$ 3,600
Payments for rent																									$ 140,890	$ 203,129		$ 129,930	$ 194,129
North Horizon Pty Ltd [Member] | Three Year Operating Lease Agreement [Member]
Related Party Transaction [Line Items]
Payments for rent							$ 2,176	$ 3,000
Former Director [Member]
Related Party Transaction [Line Items]
Loans from related party | $																									30,840			29,759
Due to related parties | $																									51,326			49,528
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Operating leases, future minimum payments due																$ 141,629																											$ 198,000
Mrs. Nathanielsz [Member]
Related Party Transaction [Line Items]
Annual salary														$ 80,904	$ 120,000
Payments form related party																									$ 2,372	$ 3,557		$ 17,714		$ 3,344
James Nathanielsz [Member]
Related Party Transaction [Line Items]
Payments form related party																		$ 3,205	$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Related Party Transaction [Line Items]
Officers compensation					$ 96,810	$ 140,000			$ 177,840
Debt conversion, converted instrument, shares issued									5,928,000
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual salary										$ 309,313	$ 400,000
Option purchase shares										0.04	0.04
Exercise price | $ / shares										$ 4,675,000
Market price										110%	110%
Granted exercise price | $ / shares										$ 4,250,000
Option term										10 years	10 years
Dr. Kenyon [Member] | Services Agreement [Member]
Related Party Transaction [Line Items]
Annual salary										$ 41,580	$ 54,000
Agreement term										3 years	3 years
Option purchase shares										0.02	0.02
Exercise price | $ / shares										$ 4,250,000
Market price										100%	100%
Option term										10 years	10 years

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 6,000	$ 34,500
Proceeds from convertible debt	$ 60,000	$ 220,000
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	28%	30%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	27%	14%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	45%	24%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage		32%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%		100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 60,000	$ 150,000
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	57,639	70,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 98,060	120,000
Lender Four [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		$ 153,256

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details)	3 Months Ended
	Sep. 30, 2024
Measurement Input, Price Volatility [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	282
Measurement Input, Price Volatility [Member] | New Derivative Instruments [Member] | Minimum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	290
Measurement Input, Price Volatility [Member] | New Derivative Instruments [Member] | Maximum [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	316
Measurement Input, Expected Term [Member] | Minimum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	3 days
Measurement Input, Expected Term [Member] | Maximum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	5 months 19 days
Measurement Input, Expected Term [Member] | New Derivative Instruments [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, term	6 months
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	4.65
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	5.53
Measurement Input, Risk Free Interest Rate [Member] | New Derivative Instruments [Member] | Minimum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	4.43
Measurement Input, Risk Free Interest Rate [Member] | New Derivative Instruments [Member] | Maximum [Member] | Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt instrument, measurement input, percentages	4.88

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities	$ 134,234	$ 133,886
Total	134,234	133,886
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Embedded conversion option liabilities	134,234	133,886
Total	$ 134,234	$ 133,886

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Beginning balance	$ 133,886
Change in fair value included in statements of operations	(52,787)	$ (303,929)
Ending balance	134,234
Derivative [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Beginning balance	133,886
Initial fair value of embedded conversion option derivative liability recorded as debt discount	60,000
Initial fair value of embedded conversion option derivative liability recorded as derivative expense	27,182
Reduction of derivative liability upon debt conversion	(34,047)
Change in fair value included in statements of operations	(52,787)
Ending balance	$ 134,234

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.0003
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 145,700	$ 110,500

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	1 Months Ended
	Oct. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Aug. 31, 2024 USD ($)	Aug. 31, 2024 AUD ($)	May 31, 2024 USD ($)	Nov. 30, 2023 USD ($)
Subsequent Event [Line Items]
Principal amount		$ 30,800	$ 57,639	$ 85,000	$ 71,629	$ 71,629
Accrued interest		2,212
Conversion fees		$ 798
Subsequent Event [Member]
Subsequent Event [Line Items]
New issuance, shares | shares	101,877,166
Debt instrument contractual conversion price | $ / shares	$ 0.0001
Principal amount	$ 10,300
Accrued interest	828
Conversion fees	$ 1,097